Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPRX
  • CUSIP: N/A
  • Web: www.catalystpharma.com
Capitalization:
  • Market Cap: $203.78 million
  • Outstanding Shares: 84,554,000
Average Prices:
  • 50 Day Moving Avg: $2.72
  • 200 Day Moving Avg: $2.28
  • 52 Week Range: $0.94 - $3.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.72
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 6.08
Profitability:
  • EBIDTA: ($16,440,000.00)
  • Return on Equity: -44.65%
  • Return on Assets: -42.03%
Debt:
  • Current Ratio: 19.43%
  • Quick Ratio: 19.43%
Misc:
  • Average Volume: 976,134 shs.
  • Beta: 1.6
  • Short Ratio: 5.67
 

Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its earnings results on Wednesday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. View Catalyst Pharmaceuticals' Earnings History.

When will Catalyst Pharmaceuticals make its next earnings announcement?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Catalyst Pharmaceuticals.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $5.50 in the next year. View Analyst Ratings for Catalyst Pharmaceuticals.

Who are some of Catalyst Pharmaceuticals' key competitors?

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:

  • Patrick James McEnany, Chairman of the Board, President, Chief Executive Officer
  • Alicia Grande CPA, Chief Financial Officer, Vice President, Treasurer
  • Steven R. Miller Ph.D., Chief Operating Officer, Chief Scientific Officer
  • David D. Muth, Executive Vice President, Chief Commercial Officer
  • M. Douglas Winship, Vice President - Regulatory Operations
  • David J. Caponera, Vice President - Patient Advocacy & Reimbursement
  • Bernardino Mosquera M.D., Vice President - Clinical Operations
  • Charles B. O'Keeffe, Lead Independent Director
  • Gary Ingenito M.D., Chief Medical Officer
  • Richard J. Daly, Director

Who owns Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.69%), Vanguard Group Inc. (4.00%), JPMorgan Chase & Co. (1.83%), State Street Corp (1.11%), Kennedy Capital Management Inc. (1.10%) and Northern Trust Corp (0.96%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, M Douglas Winship, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Who sold Catalyst Pharmaceuticals stock? Who is selling Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Berson & Corrado Investment Advisors LLC, Candriam Luxembourg S.C.A. and Tanaka Capital Management Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., State Street Corp, Northern Trust Corp, Kennedy Capital Management Inc., AJO LP, Vanguard Group Inc., FMR LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.43.


MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  162 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50 (126.34% upside)

Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017SunTrust Banks, Inc.Reiterated RatingBuy$5.00HighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$5.00LowView Rating Details
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$6.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$6.00LowView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.06)N/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.05)ViewListenView Earnings Details
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20172($0.07)($0.05)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 40.15%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017Patrick J McenanyInsiderBuy20,000$2.58$51,600.00View SEC Filing  
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Source:
DateHeadline
finance.yahoo.com logoCatalyst (CPRX) Focused on Two Lead Pipeline Candidates
finance.yahoo.com - September 18 at 5:28 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Insider Patrick J. Mcenany Purchases 20,000 Shares
www.americanbankingnews.com - September 5 at 4:46 PM
americanbankingnews.com logoCatalyst Pharmaceuticals' (CPRX) Buy Rating Reiterated at SunTrust Banks, Inc.
www.americanbankingnews.com - September 5 at 9:42 AM
americanbankingnews.com logo Analysts Expect Catalyst Pharmaceuticals, Inc. (CPRX) to Announce -$0.06 Earnings Per Share
www.americanbankingnews.com - September 3 at 10:24 PM
nasdaq.com logoCatalyst Pharmaceuticals Provides Update on the Status of its ... - Nasdaq
www.nasdaq.com - August 31 at 10:22 PM
streetinsider.com logoCatyalyst Pharma (CPRX) Provides Update on the Status of its Firdapse; Sees NDA Submitted in First Quarter of 2018
www.streetinsider.com - August 31 at 5:21 PM
globenewswire.com logoCatalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities - GlobeNewswire (press release)
globenewswire.com - August 30 at 6:31 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Provides Update on the Status of its Firdapse Development Activities
finance.yahoo.com - August 30 at 6:31 PM
nasdaq.com logoCatalyst (CPRX) Focused on Development of Pipeline Candidates
www.nasdaq.com - August 15 at 6:12 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of ($0.05) Per Share, SunTrust Banks Forecasts (NASDAQ:CPRX)
www.americanbankingnews.com - August 14 at 6:42 AM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 11:04 PM
seekingalpha.com logoCatalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:46 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target at Roth Capital
www.americanbankingnews.com - August 10 at 3:22 PM
nasdaq.com logoCatalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update - Nasdaq
www.nasdaq.com - August 9 at 5:38 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:38 PM
finance.yahoo.com logoCatalyst reports 2Q loss
finance.yahoo.com - August 9 at 5:38 PM
nasdaq.com logoWhat's in Store for Catalyst (CPRX) This Earnings Season? - Nasdaq
www.nasdaq.com - August 9 at 3:15 AM
zacks.com logoWhat's in Store for Catalyst (CPRX) This Earnings Season?
www.zacks.com - August 7 at 10:54 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Given a $6.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 7 at 6:20 PM
nasdaq.com logoCatalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Th
www.nasdaq.com - August 2 at 4:18 AM
finance.yahoo.com logoCatalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10th, 2017
finance.yahoo.com - August 1 at 6:12 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:14 AM
americanbankingnews.com logo-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter
www.americanbankingnews.com - July 29 at 7:46 AM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Short Interest Down 16.0% in July
www.americanbankingnews.com - July 28 at 1:25 AM
americanbankingnews.com logoShort Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 213.4%
www.americanbankingnews.com - July 14 at 7:04 AM
benzinga.com logo10 Biggest Mid-Day Losers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 13 at 6:42 PM
thestreet.com logoCommit To Purchase Catalyst Pharmaceuticals At $2.50, Earn 73% Annualized Using Options - TheStreet.com
www.thestreet.com - July 12 at 11:12 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - July 12 at 9:02 PM
bizjournals.com logoBiotech Stocks Ride Momentum in Anticipation of Favorable Governmental Policy Environment
www.bizjournals.com - July 12 at 6:09 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Nektar Therapeutics and Catalyst Pharmaceuticals Inc.
finance.yahoo.com - July 12 at 6:09 PM
americanbankingnews.com logoCatalyst Pharmaceuticals, Inc. (CPRX) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - July 5 at 11:48 AM
zacks.com logoWhy is Catalyst Pharmaceuticals' Stock Up 160% this Year?
www.zacks.com - June 28 at 5:25 PM
globenewswire.com logoCatalyst Pharmaceuticals Joins Russell 3000 Index - GlobeNewswire (press release)
globenewswire.com - June 26 at 10:18 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Joins Russell 3000 Index
finance.yahoo.com - June 26 at 5:16 PM
nasdaq.com logoWhy Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?
www.nasdaq.com - June 14 at 5:21 PM
americanbankingnews.com logo-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter
www.americanbankingnews.com - June 9 at 12:06 AM
nasdaq.com logoCatalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?
www.nasdaq.com - June 8 at 1:46 AM
seekingalpha.com logoCatalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 1:46 AM
finance.yahoo.com logoThree Junior Biotechs Ready to Run
finance.yahoo.com - June 7 at 3:41 PM
globenewswire.com logoCatalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:05 PM
finance.yahoo.com logoCatalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 1 at 5:03 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 22 at 4:28 PM
globenewswire.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - GlobeNewswire (press release)
globenewswire.com - May 19 at 8:35 AM
nasdaq.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - Nasdaq
www.nasdaq.com - May 18 at 11:01 AM
finance.yahoo.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium
finance.yahoo.com - May 17 at 11:29 AM
finance.yahoo.com logoCatalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare
finance.yahoo.com - May 12 at 5:00 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Issues Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 11 at 5:30 PM
zacks.com logoCatalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
www.zacks.com - May 11 at 5:04 PM
finance.yahoo.com logoInvestor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 5:04 PM
globenewswire.com logoCatalyst Pharmaceuticals Announces Poster Presentation of MuSK ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:48 PM

Social

Chart

Catalyst Pharmaceuticals (CPRX) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff